Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 58Small Cell Lung Carcinoma 22Carcinoma, Hepatocellular 17Neoplasms 15Lung Neoplasms 14Biliary Tract Neoplasms 12Neoplasm Metastasis 11Breast Neoplasms 11Recurrence 10Squamous Cell Carcinoma of Head and Neck 9Melanoma 9Carcinoma 9Advanced Solid Tumors 8Triple Negative Breast Neoplasms 7Stomach Neoplasms 7Lymphoma, Large B-Cell, Diffuse 7Liver Neoplasms 7Head and Neck Neoplasms 7Urinary Bladder Neoplasms 6Ovarian Neoplasms 6Carcinoma, Renal Cell 6Prostatic Neoplasms 5Lymphoma 5Uterine Cervical Neoplasms 4Neoplasms by Site 4Multiple Myeloma 4Lymphoma, Follicular 4Colorectal Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pancreatic Neoplasms 3

Interventions

sintilimab 1pembrolizumab 1durvalumab 1Injections 1Gemcitabine 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Biliary Tract Cancer × durvalumab × Clear all
NCT07229625 2026-01-28

A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3 Recruiting
604 enrolled
Gastrointestinal

Advanced Biliary Tract Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡